# US 2016/0237094 A1 · Therapeutic compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237094 A1
- Document ID: US20160237094A1
- Status: Published application
- Kind: A1
- Application number: 15/139,135
- Filed: 2016-04-26
- Published: 2016-08-18
- Earliest claimed: 2013-02-20
- Assignees: Kala Pharmaceuticals, Inc.
- Applicants: Kala Pharmaceuticals, Inc.
- Inventors: Winston Zapanta Ong; Pawel Wojciech Nowak; Ben C. Askew; Jinsoo Kim
- Web page: https://patentgrep.com/patent/US20160237094A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and/or preventing diseases are also provided.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is H or optionally substituted C1-6 alkyl;
R2 is optionally substituted bicyclic heterocyclyl having 1 or 2 heteroatoms;
X is a bond, —O—, or —C(═O)—;
Y is CH;
R3 is optionally substituted heteroaryl; and
n is 0, 1, 2, 3, or 4.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is CH3.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R2 is
wherein p, q, s, and t are independently 0, 1, 2, 3, or 4.

### Claim 4 (depends on 1)

The compound of claim 1, wherein X is a bond.

### Claim 5 (depends on 1)

The compound of claim 1, wherein X is —C(═O)—.

### Claim 6 (depends on 1)

The compound of claim 1, wherein n is 2.

### Claim 7 (depends on 1)

The compound of claim 1, wherein n is 1.

### Claim 8 (depends on 1)

The compound of claim 1, further represented by Formula (II) or Formula (III):
or a pharmaceutically acceptable salt thereof, wherein:
each instance of R4 is independently H, optionally substituted C1-6 alkyl, F, Cl, Br, I, CN, OH, or alkoxy;
R5 is H or a nitrogen protecting group; and
m is 0, 1, 2, 3, 4, or 5.

### Claim 9 (depends on 8)

The compound of claim 8, wherein at least one instance of R4 is CH3.

### Claim 10 (depends on 8)

The compound of claim 8, wherein at least one instance of R4 is F.

### Claim 11 (depends on 8)

The compound of claim 8, wherein at least one instance of R4 is H.

### Claim 12 (depends on 8)

The compound of claim 8, wherein R5 is H.

### Claim 13 (depends on 3)

The compound of claim 3, wherein R2 is

### Claim 14 (depends on 3)

The compound of claim 3, wherein R2 is

### Claim 15 (depends on 3)

The compound of claim 3, wherein R2 is

### Claim 16 (depends on 1)

The compound of claim 1 having a structure:

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the pharmaceutical composition is suitable for delivery to the eye.

### Claim 19 (depends on 1)

A method of treating an ocular disease comprising administering a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the ocular disease is a retinopathy or age-related macular degeneration.

### Claim 21 (depends on 19)

The method of claim 19, wherein the ocular disease is glaucoma.
